Protagonist Therapeutics, Inc. (PTGX) Insider Richard S. Shames Sells 1,512 Shares
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) insider Richard S. Shames sold 1,512 shares of the stock in a transaction on Tuesday, August 29th. The shares were sold at an average price of $17.00, for a total value of $25,704.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
Shares of Protagonist Therapeutics, Inc. (PTGX) traded down 0.91% during midday trading on Thursday, reaching $16.33. The company’s stock had a trading volume of 44,594 shares. The company’s market cap is $276.01 million. The stock has a 50-day moving average of $12.43 and a 200 day moving average of $12.09. Protagonist Therapeutics, Inc. has a 12 month low of $8.00 and a 12 month high of $26.36.
Protagonist Therapeutics (NASDAQ:PTGX) last posted its quarterly earnings data on Tuesday, August 8th. The company reported ($0.89) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by $0.70.
Several large investors have recently modified their holdings of the stock. Rhumbline Advisers acquired a new stake in shares of Protagonist Therapeutics during the second quarter worth approximately $114,000. Teachers Advisors LLC boosted its stake in Protagonist Therapeutics by 71.4% in the second quarter. Teachers Advisors LLC now owns 16,218 shares of the company’s stock valued at $183,000 after buying an additional 6,757 shares during the last quarter. Northern Capital Management LLC purchased a new stake in Protagonist Therapeutics during the second quarter valued at about $188,000. California State Teachers Retirement System boosted its stake in Protagonist Therapeutics by 8.5% in the second quarter. California State Teachers Retirement System now owns 16,600 shares of the company’s stock valued at $188,000 after buying an additional 1,300 shares during the last quarter. Finally, TIAA CREF Investment Management LLC boosted its stake in Protagonist Therapeutics by 19.5% in the second quarter. TIAA CREF Investment Management LLC now owns 23,372 shares of the company’s stock valued at $264,000 after buying an additional 3,812 shares during the last quarter. Institutional investors and hedge funds own 48.19% of the company’s stock.
A number of brokerages have commented on PTGX. BMO Capital Markets raised their price objective on Protagonist Therapeutics from $34.00 to $45.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 31st. Zacks Investment Research upgraded Protagonist Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, May 10th. BTIG Research began coverage on Protagonist Therapeutics in a research report on Friday, July 21st. They set a “buy” rating and a $36.00 price objective for the company. Finally, ValuEngine upgraded Protagonist Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $26.00.
Protagonist Therapeutics Company Profile
Protagonist Therapeutics, Inc is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company’s product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing oral peptide drugs that target biological pathways also targeted by marketed injectable antibody drugs.
Receive News & Ratings for Protagonist Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.